

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 August 2020 (27.08.2020)



(10) International Publication Number
WO 2020/172571 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2020/019291
- (22) **International Filing Date:**
21 February 2020 (21.02.2020)

- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/808,646 21 February 2019 (21.02.2019) US

- (71) **Applicant:** **ELSTAR THERAPEUTICS, INC.** [US/US];
840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US).

- (72) **Inventors:** **LOEW, Andreas**; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US). **MALHOTRA, Nidhi**; 840 Memorial Drive, 4th Floor Cambridge, Cambridge, MA 02139 (US). **KATRAGADDA, Madan**; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US). **TAN, Seng-lai**; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US). **HSU, Jonathan**; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US). **VASHI, Brian, Edward**; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US). **MAIOCCO, Stephanie, J.**; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US). **MAREK, Peter**; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US). **GUNTAS, Gurkan**; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US).

- (74) **Agent:** **COLLAZO, Diana, M.** et al.; Lando & Anastasi, LLP, 60 State Street, 23th Floor, Boston, MA 02109 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** MULTIFUNCTIONAL MOLECULES THAT BIND TO T CELL RELATED CANCER CELLS AND USES THEREOF

(57) **Abstract:** Multifunctional molecules that include i) an antigen binding domain that binds to a T cell receptor beta chain constant domain 1 or T cell receptor beta chain constant domain 2; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or cytokine inhibitor molecule; (iv) a death receptor signal enhancer; and/or (v) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

WO 2020/172571 A1